Why Did The Vanguard Group Inc. Increased Its Shares To Almost $6 Million In BPMX

silver-background-3 (14) (2)

Why Did The Vanguard Group Inc. Increased Its Shares To Almost $6 Million In BPMX – CWEB.com

Institutional investors currently hold major shares in BioPharmX Corporation(BPMX ) stock. Majority of the recent share have been purchased by Vanguard Investment firm on 5-13-2018

BioPharmX Corporation (BPMX) stock was most active stock of Wall Street Market on Tuesday. BPMX moved -1.77% to 0.19. BPMX received interesting focus from Active Investors and it has been trading on front line as seeing to it recent volume.

Statistic show the size of the acne treatment market worldwide in 2016 and a forecast for 2025, in billion U.S. dollars. In 2016, the global acne treatment market was worth some 4.9 billion dollars and was expected to grow to over 7 billion by the end of 2025.

Statistic also show the market value of skincare products in Great Britain from 2009 to 2016. The total value of the skincare market in December 2016 was measured at approximately 2.16 billion British pounds

Owner Name Date Shared Held Change (Shares) Change (%) Value (in 1,000s)
VIVO CAPITAL, LLC 05/13/2018 16,128,515 2,328,571 16.87 3,306
FRANKLIN RESOURCES INC 05/13/2018 9,749,615 0 0.00 1,999
VANGUARD GROUP INC 05/13/2018 5,498,918 3,541,971 181.00 1,127
GEODE CAPITAL MANAGEMENT, LLC 03/31/2018 671,686 347,719 107.33 138
VIRTU FINANCIAL LLC 03/31/2018 426,837 426,837 New 88
BARCLAYS PLC 03/31/2018 362,900 362,900 New 74
SUSQUEHANNA INTERNATIONAL GROUP, LLP 03/31/2018 181,335 181,335 New 37
CITADEL ADVISORS LLC 03/31/2018 146,859 146,859 New 30
MCF ADVISORS LLC 03/31/2018 105,629 105,629 New 22
JANE STREET GROUP, LLC 03/31/2018 96,941 96,941 New 20
TWO SIGMA SECURITIES, LLC 03/31/2018 93,390 47,105 101.77 19
NORTHERN TRUST CORP 03/31/2018 92,518 0 0.00 19
UBS GROUP AG 03/31/2018 70,367 36,614 108.48 14
LADENBURG THALMANN FINANCIAL SERVICES INC. 03/31/2018 64,200 0 0.00 13
CREDIT SUISSE AG/ 03/31/2018 50,000 50,000 New 10
HOLDERS SHARES
Increased Positions 17 7,708,826
Held Positions 7 15,447,095
Total Institutional Shares 27 33,878,519

On April 26th, 2018, BioPharmX reports its results for the quarter and year ended January 31st, 2018. For Q4 FY18, total operating expenses were $3.6 million, and net loss was $3.8 million.

For FY18, total operating expenses were $16.7 million, and net loss was $16.6 million. As of January 31st, 2018, cash and cash equivalents were $7.6 million.

BioPharmX Corporation (BPMX) has been working on the following pipeline for new products and FDA approvals.

HYDROPHILIC TOPICAL SYSTEM

1 Patent Issued, 21 Pending

STABILIZES

  • Hydrophilic: non-occlusive, non-oily
  • Non-lipophilic (oil-based)
  • Suitable for APIs degraded in water

FULLY SOLUBILIZES

  • Improves bioavailability
  • Not a suspension
  • Miscible w/ sebum

Higher penetration and targeted delivery

THERAPEUTICS

BPX-01-Acne

BPX-04-Rosacea

BPX-Retinoids

BPX-Combinations

INJECTABLE SYSTEM

1 Patent Pending

CROSSLINKED

  • Proprietary cross-linked injectable delivery system

SUSTAINED RELEASE

  • Prolonged release of biologics and small to mid-sized molecules

Suitable for aesthetics

AESTHETICS

BPX-02

ENCAPSULATION SYSTEM

3 Patents Issued, 4 Pending

ISOLATES

  • Separates hydrophilic APIs from boundary layer

ENCAPSULATES

  • Encapsulates between the hydrophilic and hydrophobic phases of emulsion

Emulsion feels smooth to the touch

COSMETICS

IODINE SYSTEM

1 Patent Allowed, 3 Pending

STABILIZES

  • Oral delivery of iodide and iodate
  • Patented formulation stabilizes iodine

TARGETS

  • Delivery to targeted mammary cells
  • Apoptotic and anti-proliferative effects

Commercially available product since 2014

WOMEN’S HEALTH

BPX-03

Women’s Health Asset for Strategic Partnerships

The patent (U.S. Patent No. 9,918,998), entitled “Pharmaceutical Tetracycline Composition For Dermatological Use,” covers a topical composition comprised of minocycline or another tetracycline-class drug and a method for making such compositions. The patent also covers treatments of dermatological inflammation or infection using a minocycline composition. Current formulations protected by the patent include BPX-01 for the treatment of acne and BPX-04 for the treatment of rosacea.

This is the fourth U.S. patent issuance BioPharmX (BPMX) has received. Three earlier-issued U.S. patents protect the company’s encapsulation delivery system, which can isolate the API. The most recent of these patents, U.S. Patent No. 9,901,586, entitled “Dosage Form Comprising an Active Ingredient and a Plurality of Solid Porous Microcarriers,” was granted Feb. 27.

The US 9,918,998 patent protects tetracycline-class products carried by BioPharmX’s innovative delivery system, which for the first time stabilizes and fully solubilizes these drugs to make them effective in a topical formulation. This includes products that use other tetracycline-class drugs as well as combination products that combine antibiotics with other drugs, for example retinoids.

“This patent protection is a significant milestone for BioPharmX,” said President and Co-founder Anja Krammer. “It recognizes that our development of a topical tetracycline-class drug, something that has eluded the pharmaceutical industry since minocycline was first commercially used in the 1970s, is truly unique.”

BioPharmX has successfully completed a phase 2b trial for BPX-01 for acne and is in phase 3 readiness. The company has reported positive interim results from a feasibility study for BPX-04 for rosacea and is preparing for a phase 2 trial.

Anthony Vendetti from Maxim Group maintained a Buy rating on BioPharmX Corp (NYSE: BPMX), with a price target of $1.50.

The Industry Biotechnology & Medical Research also suggest that  BioPharmX Corporation (BPMX) is currently the cheapest stock against major companies below:

PTIE Pain Therapeutics Inc Com New 4/23/18 10.15 30.46%
SNMX Senomyx Inc Com 5/14/18 1.42 8.40%
VRTX Vertex Pharmaceuticals Inc Com 5/13/18 157.24 0.81%
ARQL Arqule Inc Com 5/18/18 3.39 0.00%
ICLR Icon Plc Shs 5/21/18 125.74 0.00%

Institutional ownership trends suggest that the stock is cheap and the insider trading data indicates that insiders are bullish. Technical indicators also suggest that BioPharmX Corporation (BPMX) , is undervalued.  

CWEB Analysts have Reiterate a Buy Rating for BioPharmX Corporation (BPMX)  and a Price Target of $7 within 12 months.

A possible partnership or major investment for  BioPharmX Corporation (BPMX)  is strongly possible in this coming month by big pharmaceutical company.

Read Full Article and Videos CWEB.com – Trending News, Blog, Shopping

Chart
BPMX data by YCharts

 

[youtube https://www.youtube.com/watch?v=9TXBP1t2rUc&w=560&h=315]

Spread the love

Leave a Reply

Your email address will not be published. Required fields are marked *


This site uses Akismet to reduce spam. Learn how your comment data is processed.

  • News Sources

0
Loading...